Consultation: Electronic media in prescription drug labelling draft guidance document
From Health Canada
Current status: Open
Opened on March 12, 2021 and will close to new input on May 7, 2021.
This draft guidance describes Health Canada's expectations for drug sponsors interested in distributing information about a prescription drug product using an electronic platform (for example, website, mobile application) that is linked to that product's label. It also provides information on how sponsors can apply to incorporate an electronic platform into their prescription drug label.
This draft guidance is based on Health Canada's existing legal framework. As such, information distributed through an electronic platform generally cannot replace information that is required by law to appear on a drug's physical label. The use of electronic media in prescription drug labelling is considered voluntary and supplementary to existing legal requirements. Furthermore, this document does not address the appropriateness of disseminating labelling materials that have been traditionally distributed through print (for example, package inserts) using an electronic platform.
How to participate
Send us an email
Send an email to email@example.com with your ideas or comments to make yourself heard.
Who is the focus of this consultation
Health Canada wants to hear from:
- general public
- health professionals
- other interested parties
Goals of the consultation
We are seeking comments on the draft guidance. We will use input gathered through this consultation to finalize the guidance document.
Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C5
Report a problem or mistake on this page
- Date modified: